Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting

BMC Research Notes

John M Kaldor³  Peter Siba²  John Millan⁵  James Neo²  Martha Kupul²  Joyce Sauk¹  Angela Kelly⁶  Herick Aeno²  Voletta Fiya²  Lisa Fitzgerald⁴  Andrew Vallely² 

[1] HOPE Worldwide, Port Moresby, Papua New Guinea;Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea;The Kirby Institute, The University of New South Wales, Sydney, NSW, 2052, Australia;School of Population Health, University of Queensland, Brisbane, Australia;Sexual Health and Disease Control Branch, National Department of Health, Port Moresby, Papua New Guinea;International HIV Research Group, School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia

关键词: Papua New Guinea;    HIV prevention;    Acceptability;    Vaginal microbicide;   

Others  :  1165299
DOI  :  10.1186/1756-0500-5-613

 received in 2012-02-07, accepted in 2012-10-18,  发布年份 2012

【 摘 要 】

Background

The acceptability of female-controlled biomedical prevention technologies has not been established in Papua New Guinea, the only country in the Pacific region experiencing a generalised, moderate-prevalence HIV epidemic. Socio-cultural factors likely to impact on future product uptake and effectiveness, such as women’s ability to negotiate safer sexual choices, and intravaginal hygiene and menstrual practices (IVP), remain unclear in this setting.

Methods

A mixed-method qualitative study was conducted among women and men attending a sexual health clinic in Port Moresby. During in-depth interviews, participants used copies of a hand-drawn template to indicate how they wash/clean the vulva and/or vagina. Interviewers pre-filled commercially available vaginal applicators with 2-3mL KY Jelly® to create a surrogate vaginal microbicide product, which was demonstrated to study participants.

Results

A total of 28 IDIs were conducted (women=16; men=12). A diverse range of IVP were reported. The majority of women described washing the vulva only with soap and water as part of their daily routine; in preparation for sex; and following sexual intercourse. Several women described cleaning inside the vagina using fingers and soap at these same times. Others reported cleaning inside the vagina using a hose connected to a tap; using vaginal inserts, such as crushed garlic; customary menstrual ‘steaming’ practices; and the use of material fragments, cloth and newspaper to absorb menstrual blood. Unprotected sex during menstruation was common. The majority of both women and men said that they would use a vaginal microbicide gel for HIV/STI protection, should a safe and effective product become available. Microbicide use was considered most appropriate in ‘high-risk’ situations, such as sex with non-regular, transactional or commercial partners. Most women felt confident that they would be able to negotiate vaginal microbicide use with male sexual partners but if necessary would be prepared to use product covertly.

Conclusions

Notional acceptability of a vaginal microbicide gel for HIV/STI prevention was high among both women and men. IVP were diverse in nature, socio-cultural dimensions and motivators. These factors are likely to impact on the future acceptability and uptake of vaginal microbicides and other biomedical HIV prevention technologies in this setting.

【 授权许可】

   
2012 Vallely et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]UNAIDS: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS; 2010.
• [2]McCormack S, Hayes R, Lacey CJ, Johnson AM: Science, medicine, and the future. Microbicides in HIV prevention. BMJ 2001, 322:410-413.
• [3]Balzarini J, Van Damme L: Microbicide drug candidates to prevent HIV infection. Lancet 2007, 369(9563):787-797.
• [4]McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, et al.: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376(9749):1329-1337.
• [5]Nuttall J, Romano J, Douville K, Galbreath C, Nel A, Heyward W, Mitchnick M, Walker S, Rosenberg Z: The Future of HIV Prevention: Prospects for an Effective Anti-HIV Microbicide. Infect Dis Clin North Am 2007, 21(1):219-239.
• [6]Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, et al.: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010, 329:1168-1174.
• [7]CONRAD: FDA and CONRAD Chart U.S. Regulatory Path for 1% Tenofovir Gel for HIV Prevention. 2010. Available at: http://www.conrad.org/media/news/88_CONRAD%20FDA%20Meeting%20Release%2020%20Final.doc webcite
• [8]Akil A, Dezzutti C, Moncla B, Parniak M, Graebing P, Cost M, Dumanli I, Rohan LC: Quick-dissolve films as drug delivery systems for combination microbicides. In International Microbicides Conference 2010. USA: Pittsburgh PA; 22-25 May 2010.
• [9]Wang L, Dezzutti C, Moncla B, Parniak M, Mallipeddi R, Friend D, Rohan LC: Formulation of a Tenofovir containing quick-dissolve film product. In International Microbicides Conference 22–25 May 2010. USA: Pittsburgh PA; 2010.
• [10]Garg S, Gupta J, Othman A, Singh S: Development and evaluation of novel solid dosage forms of Tenofovir. In International Microbicides Conference 22–25 May 2010. USA: Pittsburgh PA; 2010.
• [11]Mantell JE, Myer L, Carballo-Dieguez A, Stein Z, Ramjee G, Morar NS, Harrison PF: Microbicide acceptability research: current approaches and future directions. Soc Sci Med 2005, 60(2):319-330.
• [12]Foss AM, Vickerman PT, Heise L, Watts CH: Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003, 17(8):1227-1237.
• [13]Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, Mntambo M, Phillip J, Watts C, Pool R: The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care 2008, 20(6):733-740.
• [14]Wilson DP, Bodine EN, Smith RJ, Blower SM: Care should be taken when promoting microbicide use among sex workers who are able to use condoms consistently. AIDS 2005, 19(17):2044-2046.
• [15]Gafos M, Mzimela M, Sukazi S, Pool R, Montgomery CM, Elford J: Intravaginal insertion in KwaZulu Natal: new insights into sexual practices and preferences in the context of microbicide gel use. Cult Health Sex 2010, 12(8):929-42.
• [16]Pool R, Whitworth J, Green G, Mbonye AK, Harrison S, Wilkinson J, Hart G: An acceptability study of female controlled methods of protection against HIV and STDs in south-western Uganda. Internat J STD AIDS 2000, 11(3):162-167.
• [17]Myer L, Denny L, De Souza M, Barone MA, Wright TC Jr, Kuhn L: Intravaginal practices, HIV and other sexually transmitted diseases among South African women. Sex Transm Dis 2004, 31(3):174-179.
• [18]Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L: Intravaginal practices, bacterial vaginosis, and women’s susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005, 5(12):786-794.
• [19]Myer L, Denny L, de Souza M, Wright TC Jr, Kuhn L: Distinguishing the temporal association between women’s intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol 2006, 163(6):552-560.
• [20]van de Wijgert JH, Morrison CS, Cornelisse PG, Munjoma M, Moncada J, Awio P, Wang J, Van der Pol B, Chipato T, Salata RA, et al.: Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 2008, 48(2):203-210.
• [21]van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, Byamugisha JK, Padian N, Salata RA: Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis 2009, 36(6):357-364.
• [22]Hilber AM, Francis SC, Chersich M, Scott P, Redmond S, Bender N, Miotti P, Temmerman M, Low N: Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS One 2010, 5(2):e9119.
• [23]Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert JH, Hayes RJ, Baeten JM, Brown J, Delany-Moretlwe S, et al.: Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 2011, 8(2):e1000416.
• [24]Allen CF, Desmond N, Chiduo B, Medard L, Lees SS, Vallely A, Francis SC, Ross DA, Hayes RJ: Intravaginal and menstrual practices among women working in food and recreational facilities in Mwanza, Tanzania: implications for microbicide trials. AIDS Behav 2010, 14(5):1169-1181.
• [25]Braunstein S, van de Wijgert J: Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt) 2005, 14(5):424-433.
• [26]Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, Ndinya-Achola J: Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses 2011, 27(10):1067-72.
• [27]Woodsong C, Alleman P: Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev 2008, 20(2):171-187.
• [28]Lees S, Desmond N, Allen C, Bugeke G, Vallely A, Ross D: Sexual risk behaviour for women working in recreational venues in Mwanza, Tanzania: considerations for the acceptability and use of vaginal microbicide gels. Cult Health Sex 2009, 11(6):581-595.
• [29]Hull T, Hilber AM, Chersich MF, Bagnol B, Prohmmo A, Smit JA, Widyantoro N, Utomo ID, Francois I, Tumwesigye NM, et al.: Prevalence, motivations, and adverse effects of vaginal practices in Africa and Asia: findings from a multicountry household survey. J Womens Health (Larchmt) 2011, 20(7):1097-1109.
• [30]Martin Hilber A, Hull TH, Preston-Whyte E, Bagnol B, Smit J, Wacharasin C, Widyantoro N: A cross cultural study of vaginal practices and sexuality: implications for sexual health. Soc Sci Med 2010, 70(3):392-400.
• [31]Reed BD, Ford K, Wirawan DN: The Bali STD/AIDS study: association between vaginal hygiene practices and STDs among sex workers. Sex Transm Infect 2001, 77(1):46-52.
• [32]Reiff M, Wade C, Chao MT, Kronenberg F, Cushman LF: Health practices and vaginal microbicide acceptability among urban black women. J Womens Health (Larchmt) 2008, 17(8):1345-1351.
• [33]Scorgie F, Smit JA, Kunene B, Martin-Hilber A, Beksinska M, Chersich MF: Predictors of vaginal practices for sex and hygiene in KwaZulu-Natal, South Africa: findings of a household survey and qualitative inquiry. Cult Health Sex 2011, 13(4):381-398.
• [34]Turner AN, Morrison CS, Munjoma MW, Moyo P, Chipato T, Van De Wijgert JH: Vaginal practices of HIV-negative Zimbabwean women. Infect Dis Obstet Gynecol 2010. 2010
• [35]Veldhuijzen N, Nyinawabega J, Umulisa M, Kankindi B, Geubbels E, Basinga P, Vyankandondera J, Van De Wijgert J: Preparing for microbicide trials in Rwanda: focus group discussions with Rwandan women and men. Cult Health Sex 2006, 8(5):395-406.
• [36]Sharma A, Bukusi E, Posner S, Feldman D, Ngugi E, Cohen CR: Sex preparation and diaphragm acceptability in sex work in Nairobi, Kenya. Sex Health 2006, 3(4):261-268.
• [37]UNAIDS/WHO: AIDS epidemic update: December 2009. Geneva: UNAIDS/WHO; 2009.
• [38]Azim T, Khan SI, Haseen F, Huq NL, Henning L, Pervez MM, Chowdhury ME, Sarafian I: HIV and AIDS in Bangladesh. J Health Popul Nutr 2008, 26(3):311-324.
• [39]Azim T, Rahman M, Alam MS, Chowdhury IA, Khan R, Reza M, Chowdhury EI, Hanifuddin M, Rahman AS: Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users. Int J STD AIDS 2008, 19(5):327-331.
• [40]Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho DD, Jiang Y, Zhang L: The changing face of HIV in China. Nature 2008, 455(7213):609-611.
• [41]Wang L, Wang N, Li D, Jia M, Gao X, Qu S, Qin Q, Wang Y, Smith K: The 2007 Estimates for People at Risk for and Living With HIV in China: Progress and Challenges. J Acquir Immune Defic Syndr 2009, 50(4):414-418.
• [42]Iskandar S, Basar D, Hidayat T, Siregar IM, Pinxten L, van Crevel R, Van der Ven AJ, De Jong CA: High risk behavior for HIV transmission among former injecting drug users: a survey from Indonesia. BMC Public Health 2010, 10:472. BioMed Central Full Text
• [43]Jacubowski N: Marriage is not a safe place: heterosexual marriage and HIV-related vulnerability in Indonesia. Cult Health Sex 2008, 10(1):87-97.
• [44]Magnani R, Riono P, Nurhayati A, Saputro E, Mustikawati D, Anartati A, Prabawanti C, Majid N, Morineau G: Sexual risk behaviours, HIV and other sexually transmitted infections among female sex workers in Indonesia. Sex Transm Infect 2010, 86(5):393-9.
• [45]Khan AA, Awan AB, Qureshi SU, Razaque A, Zafar ST: Large sharing networks and unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha. Pakistan. Harm Reduct J 2009, 6:13. BioMed Central Full Text
• [46]Khan AA, Khan A: The HIV epidemic in Pakistan. J Pak Med Assoc 2010, 60(4):300-307.
• [47]NACO: UNGASS country progress report 2008: India. New Delhi: National AIDS Control Organisation, Ministry of Health and Family Welfare; 2008.
• [48]Vallely A, Page A, Dias S, Siba P, Lupiwa T, Law G, Millan J, Wilson D, Murray JM, Toole M, et al.: The prevalence of sexually transmitted infections in Papua New Guinea: A systematic review and meta-analysis. PLoS One 2010, 5(12):e15586.
• [49]Fotinatos N, Warmington A, Walker T, Pilbeam M: Trichomonas vaginalis in Vanuatu. Aust J Rural Health 2008, 16(1):23-27.
• [50]Haddow LJ, Sullivan EA, Taylor J, Abel M, Cunningham AL, Tabrizi S, Mindel A: Herpes simplex virus type 2 (HSV-2) infection in women attending an antenatal clinic in the South Pacific island nation of Vanuatu. Sex Transm Dis 2007, 34(5):258-261.
• [51]Zenner D, Russell S: Sexually transmitted diseases and HIV/AIDS in Vanuatu: a cause for concern and action. N Z Med J 2005, 118(1220):U1610.
• [52]Cliffe SJ, Tabrizi S, Sullivan EA: Chlamydia in the Pacific region, the silent epidemic. Sex Transm Dis 2008, 35(9):801-806.
• [53]WPRO: Second Generation Surveillance Surveys of HIV, other STIs and Risk Behaviours in 6 Pacific Island Countries (2004–2005). Manila: World Health Organization Western Pacific Regional Office; 2006.
• [54]National AIDS Council Secretariat and National Department of Health: The 2007 Estimation Report on the HIV Epidemic in Papua New Guinea. Port Moresby: National AIDS Council of Papua New Guinea; 2007.
• [55]Sladden T: Twenty years of HIV surveillance in the Pacific - what do the data tell us and what do we still need to know? Pacific Health Dialogue 2005, 12(2):23-37.
• [56]Duke T: HIV in Papua New Guinea: the need for practical action, and a focus on human resources and health systems for women and children. J Paediatr Child Health 2008, 44(11):611-612.
• [57]UNAIDS/WHO: Oceania: AIDS epidemic update. Regional Summary. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); 2008.
• [58]National_AIDS_Council: Papua New Guinea National Strategic Plan on HIV/AIDS, 2006–2010. Port Moresby: National AIDS Council; 2005.
• [59]Worth H, Henderson K: AIDS is a tear in the social fabric of PNG: HIV and its impact 2005–2025. Health Sociology Review 2006, 15(13):293-304.
• [60]AusAID: Impacts of HIV/AIDS 2005–2025 in Papua New Guinea, Indonesia and East Timor. Final Report of HIV Epidemiological Modelling and Impact Study. Canberra, Australia: Australian Agency for International Development, Commonwealth of Australia; 2006.
• [61]Vallely A, Shagi C, Kasindi S, Desmond N, Lees S, Chiduo B, Hayes R, Allen C, Ross D: The benefits of participatory methodologies to develop effective community dialogue in the context of a microbicide trial feasibility study in Mwanza. Tanzania. BMC Public Health 2007, 7:133. BioMed Central Full Text
• [62]Whitehead SJ, Kilmarx PH, Blanchard K, Manopaiboon C, Chaikummao S, Friedland B, Achalapong J, Wankrairoj M, Mock P, Thanprasertsuk S, et al.: Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 2006, 20(17):2141-2148.
• [63]Kilmarx PH, van de Wijgert JH, Chaikummao S, Jones HE, Limpakarnjanarat K, Friedland BA, Karon JM, Manopaiboon C, Srivirojana N, Yanpaisarn S, et al.: Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr 2006, 43(3):327-334.
• [64]Kilmarx PH, Blanchard K, Chaikummao S, Friedland BA, Srivirojana N, Connolly C, Witwatwongwana P, Supawitkul S, Mock PA, Chaowanachan T, et al.: A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis 2008, 35(3):226-232.
• [65]Jones HE, Chaikummao S, van de Wijgert JH, Friedland BA, Manopaiboon C, Witwatwongwana P, Wankrairot M, Chantharojwong N, Kilmarx PH: Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand. J Womens Health (Larchmt) 2009, 18(7):1003-1010.
• [66]Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, Mwafulirwa L, Khumalo-Sakutukwa G, Celentano DD: Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 2004, 94(7):1159-1164.
• [67]Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L: Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005, 19(18):2157-2163.
• [68]Joshi S, Solomon S, Mayer K, Mehendale S: Preparing for efficacy trials of vaginal microbicides in Indian women. Indian J Med Res 2005, 121(4):502-509.
• [69]Joshi S, Joglekar N, Ghate M, Unni J, Risbud A, Bentley M, Shepherd M, Bollinger R, Mehendale S: Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J Med Res 2003, 117:152-157.
• [70]Joglekar NS, Joshi SN, Deshpande SS, Parkhe AN, Katti UR, Mehendale SM: Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, ‘Praneem polyherbal tablet’, in Pune, India. Trans R Soc Trop Med Hyg 2010, 104(6):412-415.
• [71]Joglekar N, Joshi S, Kakde M, Fang G, Cianciola M, Reynolds S, Mehendale S: Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007, 19(6):817-821.
• [72]Greene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE: Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex 2010, 12(7):739-54.
• [73]Vallely A, Lees S, Shagi C, Kasindi S, Soteli S, Kavit N, Vallely L, McCormack S, Pool R, Hayes RJ: How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza. Tanzania. BMC Med Ethics 2010, 11:10. BioMed Central Full Text
• [74]Lees S, Cook C, Vallely A, Desmond N, Allen C, Kiro K, Wamoyi J, Medard L, Pool R, Hayes RJ, et al.: Comparison of sexual behavior data collected using a coital diary and a clinic-based interview during a microbicide pilot study in Mwanza, Tanzania. Sex Transm Dis 2010, 37(8):497-501.
• [75]Short RV: New ways of preventing HIV infection: thinking simply, simply thinking. Philos Trans R Soc Lond B Biol Sci 2006, 361(1469):811-820.
• [76]Anukam KC, Reid G: In vitro evaluation of the viability of vaginal cells (VK2/E6E7) and probiotic Lactobacillus species in lemon juice. Sex Health 2009, 6(1):67-74.
• [77]Fletcher PS, Harman SJ, Boothe AR, Doncel GF, Shattock RJ: Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology 2008, 5:3. BioMed Central Full Text
• [78]Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA: Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. J Womens Health (Larchmt) 2007, 16(7):1041-1051.
• [79]Mauck CK, Ballagh SA, Creinin MD, Weiner DH, Doncel GF, Fichorova RN, Schwartz JL, Chandra N, Callahan MM: Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008, 49(3):243-250.
• [80]Sagay AS, Imade GE, Onwuliri V, Egah DZ, Grigg MJ, Musa J, Thacher TD, Adisa JO, Potts M, Short RV: Genital tract abnormalities among female sex workers who douche with lemon/lime juice in Nigeria. Afr J Reprod Health 2009, 13(1):37-45.
• [81]Kalichman SC, Simbayi LC: Sexual exposure to blood and increased risks for heterosexual HIV transmission in Cape Town, South Africa. Afr J Reprod Health 2004, 8(2):55-58.
• [82]Malamba SS, Wagner HU, Maude G, Okongo M, Nunn AJ, Kengeya-Kayondo JF, Mulder DW: Risk factors for HIV-1 infection in adults in a rural Ugandan community: a case–control study. AIDS 1994, 8(2):253-257.
• [83]Mattson CL, Bailey RC, Agot K, Ndinya-Achola JO, Moses S: A nested case–control study of sexual practices and risk factors for prevalent HIV-1 infection among young men in Kisumu, Kenya. Sex Transm Dis 2007, 34(10):731-736.
• [84]Sarkar K, Bal B, Mukherjee R, Niyogi SK, Saha MK, Bhattacharya SK: Epidemiology of HIV infection among brothel-based sex workers in Kolkata, India. J Health Popul Nutr 2005, 23(3):231-235.
• [85]Tanfer K, Aral SO: Sexual intercourse during menstruation and self-reported sexually transmitted disease history among women. Sex Transm Dis 1996, 23(5):395-401.
• [86]Brabin L, Roberts SA, Fairbrother E, Mandal D, Higgins SP, Chandiok S, Wood P, Barnard G, Kitchener HC: Factors affecting vaginal pH levels among female adolescents attending genitourinary medicine clinics. Sex Transm Infect 2005, 81(6):483-487.
• [87]Farage MA, Neill S, MacLean AB: Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv 2009, 64(1):58-72.
• [88]Weinberg A, Enomoto L, Marcus R, Canniff J: Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation. J Reprod Immunol 2011, 89(1):70-77.
• [89]Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Crook A, Nunn A, et al.: A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One 2010, 5(7):e11600.
• [90]Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Crook A, Nunn A, et al.: Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS One 2010, 5(7):e11632.
• [91]Allen CF, Lees SS, Desmond NA, Der G, Chiduo B, Hambleton I, Knight L, Vallely A, Ross DA, Hayes RJ: Validity of coital diaries in a feasibility study for the microbicides development programme trial among women at high risk of HIV/AIDS in Mwanza, Tanzania. Sex Transm Infect 2007, 83(6):490-496. discussion 496–497
• [92]Gray RT, Murray JM, Vallely A, Lote N, Lupiwa T, Millan J, Daoni E, Kaldor J, Siba P, Wilson D: The PNG HIV Model: Explaining the past, describing the present, and forecasting the future of the HIV epidemic in PNG. In Australasian HIV/AIDS Conference, 26 - 28 September 2011. Canberra, Australia; 2011.
• [93]Gray RT, Murray JM, Wilson DP, Vallely A, Kaldor J: The PNG HIV Model - Summary and Results: Explaining the past, describing the present, and forecasting the future of the HIV epidemic in PNG. Sydney, Australia: The Kirby Institute, The University of New South Wales; 2011.
• [94]Wilson DP, Coplan PM: Mathematical models and health economic aspects of microbicides. Curr Opin HIV AIDS 2008, 3:587-592.
• [95]Smith RJ, Bodine EN, Wilson DP, Blower SM: Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 2005, 19:413-421.
• [96]Wilson DP, Coplan PM, Wainberg MA, Blower SM: The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Nat Acad Sciences 2008, 105(28):9835-9840.
• [97]Tynan A, Vallely A, Kelly A, Law G, Milan J, Siba P, Kaldor J, Hill P: Vasectomy as a proxy: extrapolating health system lessons to male circumcision as an HIV prevention strategy in Papua New Guinea. BMC Health Serv Res 2012, 12(1):299. BioMed Central Full Text
• [98]Tynan A, Vallely A, Kelly A, Kupul M, Law G, Milan J, Siba P, Kaldor J, Hill PS: Health workers, health facilities and penile cutting in Papua New Guinea: Implications for male circumcision as an HIV prevention strategy. PNG Med J 2012. In Press